# IMMUNOLOGIC CONTROL OF TUMOR CELL MIGRATION

> **NIH NIH R01** · HAHNEMANN UNIVERSITY · 1987 · $132,745

## Abstract

Lymphokine preparations of human or murine origin contain a low molecular
weight protein, TMIF, that can reversibly inhibit the migration of a
variety of tumor cells, obtained from serially passaged animal tumors as
well as from spontaneous human neoplasms.  These preparations can also
inhibit the binding of tumor cells to endothelium.  It is not yet known
whether the responsible factor for this latter activity (TBIF) is distinct
from TMIF.  These factors are not cytotoxic.  The existence of these
activities, appearing within a narrow molecular weight range (5,00-10,000
daltons) different from that of other known lymphokines, lead to the
hypothesis that there is a distinct class of lymphokine mediators with the
common feature of influencing functional properties of tumor cells.  Since
these functions are those that are involved in the expression of malignant
potential, these mediators could have therapeutic application.  They can be
partially purified by simple sizing procedures to exclude other categories
of lymphokines, as well as small molecular weight agents such as
prostaglandins.  We now propose to purify these factors to homogeneity by
physicochemical techniques such as HPLC and FPLC, as well as immunoaffinity
chromatography.  Purified TMIF and TBIF, monoclonal antibodies prepared
against these factors, and monoclonal antibodies against the tumor cell
surface binding site responsible for the attachment of that cell to
endothelium will be used to study the mechanisms by which these lymphokines
exert their effects, with special attention to their interaction with
surface receptors on their target cells.  Although the bulk of these
studies involve in vitro effects, an attempt will be made to demonstrate
that TMIF and/or TBIF are effective in vivo as well, utilizing a tumor
arrest model.

## Key facts

- **NIH application ID:** 3170303
- **Project number:** 7R01CA032319-05
- **Recipient organization:** HAHNEMANN UNIVERSITY
- **Principal Investigator:** MARION C. COHEN
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1987
- **Award amount:** $132,745
- **Award type:** 7
- **Project period:** 1987-07-01 → 1989-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3170303

## Citation

> US National Institutes of Health, RePORTER application 3170303, IMMUNOLOGIC CONTROL OF TUMOR CELL MIGRATION (7R01CA032319-05). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3170303. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*